AMRX
Price
$11.52
Change
-$0.05 (-0.43%)
Updated
Nov 19, 01:56 PM (EDT)
Capitalization
3.64B
105 days until earnings call
Intraday BUY SELL Signals
IRWD
Price
$3.19
Change
+$0.08 (+2.57%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
507.56M
85 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRX vs IRWD

Header iconAMRX vs IRWD Comparison
Open Charts AMRX vs IRWDBanner chart's image
Amneal Pharmaceuticals
Price$11.52
Change-$0.05 (-0.43%)
Volume$749
Capitalization3.64B
Ironwood Pharmaceuticals
Price$3.19
Change+$0.08 (+2.57%)
Volume$23.44K
Capitalization507.56M
AMRX vs IRWD Comparison Chart in %
AMRX
Daily Signal:
Gain/Loss:
IRWD
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMRX vs. IRWD commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and IRWD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (AMRX: $11.57 vs. IRWD: $3.12)
Brand notoriety: AMRX and IRWD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 61% vs. IRWD: 123%
Market capitalization -- AMRX: $3.64B vs. IRWD: $507.56M
AMRX [@Pharmaceuticals: Generic] is valued at $3.64B. IRWD’s [@Pharmaceuticals: Generic] market capitalization is $507.56M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileIRWD’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • IRWD’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRX is a better buy in the long-term than IRWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while IRWD’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • IRWD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IRWD is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а -3.14% price change this week, while IRWD (@Pharmaceuticals: Generic) price change was +7.96% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.86%. For the same industry, the average monthly price growth was -6.64%, and the average quarterly price growth was +28.04%.

Reported Earning Dates

AMRX is expected to report earnings on Mar 04, 2026.

IRWD is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.86% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($3.64B) has a higher market cap than IRWD($508M). AMRX has higher P/E ratio than IRWD: AMRX (1159.00) vs IRWD (17.39). AMRX YTD gains are higher at: 46.149 vs. IRWD (-29.571). AMRX has higher annual earnings (EBITDA): 584M vs. IRWD (79.6M). IRWD has more cash in the bank: 92.9M vs. AMRX (71.5M). IRWD has less debt than AMRX: IRWD (599M) vs AMRX (2.58B). AMRX has higher revenues than IRWD: AMRX (2.85B) vs IRWD (309M).
AMRXIRWDAMRX / IRWD
Capitalization3.64B508M716%
EBITDA584M79.6M734%
Gain YTD46.149-29.571-156%
P/E Ratio1159.0017.396,665%
Revenue2.85B309M923%
Total Cash71.5M92.9M77%
Total Debt2.58B599M431%
FUNDAMENTALS RATINGS
AMRX vs IRWD: Fundamental Ratings
AMRX
IRWD
OUTLOOK RATING
1..100
8323
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
44100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3934
P/E GROWTH RATING
1..100
13100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRWD's Valuation (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that IRWD’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for IRWD (100) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew somewhat faster than IRWD’s over the last 12 months.

AMRX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as IRWD (100) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew similarly to IRWD’s over the last 12 months.

IRWD's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as AMRX (39) in the Pharmaceuticals Major industry. This means that IRWD’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's P/E Growth Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for IRWD (100) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew significantly faster than IRWD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXIRWD
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 7 days ago
66%
Declines
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signal:
Gain/Loss:
IRWD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EACPX62.66N/A
N/A
Eaton Vance Tax-Managed Multi-Cap Gr A
SLPIX117.37N/A
N/A
ProFunds Small Cap Inv
ETCHX42.01N/A
N/A
Eventide Healthcare & Life Sciences C
PMYZX47.29-0.31
-0.65%
Putnam Core Equity Fund R
VNSAX23.94-0.25
-1.03%
Natixis Vaughan Nelson Select A